Cargando…

High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study

BACKGROUND AND OBJECTIVES: The evidence for high-volume hemofiltration plus hemoperfusion (HVHF&HP) for hyperlipidemic severe acute pancreatitis (HL-SAP) is anecdotal. The purpose of our study was to evaluate the efficacy of HVHF&HP for HL-SAP in a prospective controlled study. DESIGN AND SE...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shiren, He, Lijie, Bai, Ming, Liu, Hongbao, Li, Yangping, Li, Li, Yu, Yan, Shou, Meilan, Jing, Rui, Zhao, Liyuan, Huang, Chen, Wang, Hanmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074380/
https://www.ncbi.nlm.nih.gov/pubmed/26506968
http://dx.doi.org/10.5144/0256-4947.2015.352
_version_ 1783344396527206400
author Sun, Shiren
He, Lijie
Bai, Ming
Liu, Hongbao
Li, Yangping
Li, Li
Yu, Yan
Shou, Meilan
Jing, Rui
Zhao, Liyuan
Huang, Chen
Wang, Hanmin
author_facet Sun, Shiren
He, Lijie
Bai, Ming
Liu, Hongbao
Li, Yangping
Li, Li
Yu, Yan
Shou, Meilan
Jing, Rui
Zhao, Liyuan
Huang, Chen
Wang, Hanmin
author_sort Sun, Shiren
collection PubMed
description BACKGROUND AND OBJECTIVES: The evidence for high-volume hemofiltration plus hemoperfusion (HVHF&HP) for hyperlipidemic severe acute pancreatitis (HL-SAP) is anecdotal. The purpose of our study was to evaluate the efficacy of HVHF&HP for HL-SAP in a prospective controlled study. DESIGN AND SETTING: Prospective controlled pilot study between May 2010 and May 2013 in a hospital intensive care unit. PATIENTS AND METHODS: HL-SAP patients chose conventional treatment alone (the control group) or conventional treatment combined with the experimental protocol (the HVHF&HP group) and were prospectively followed in our hospital. APACHE II score, SOFA score, ICU and hospital stay duration, and serum biomarkers were considered endpoints. RESULTS: Ten HL-SAP patients accepted conventional treatment alone (the control group) and 10 patients underwent HVHF&HP combined with conventional treatment (the HVHF&HP group). The APACHE II score, SOFA score, systolic blood pressure, diastolic blood pressure, heart rate, serum amylase, and serum creatinine were significantly reduced after the HVHF&HP treatment. The changes in these variables were significantly different between the HVHF&HP and control group at 48 hours after the initiation of treatment. Patients in the HVHF&HP group had a significantly shorter ICU stay (P=.015). The reduction in serum triglyceride and cholesterol in the HVHF&HP group after 2, 6, 12, 24, and 48 hours was greater than the control group. All of the tested serum cytokines were significantly decreased after HVHF&HP treatment (P<.05). However, in patients who underwent conventional treatment alone, there was no significant change in the serum cytokines. CONCLUSION: This study suggests that the addition of HVHF&HP to conventional treatment for HL-SAP patients may be superior to conventional treatment alone for the improvement of serum biomarkers and clinical outcomes.
format Online
Article
Text
id pubmed-6074380
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher King Faisal Specialist Hospital and Research Centre
record_format MEDLINE/PubMed
spelling pubmed-60743802018-09-21 High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study Sun, Shiren He, Lijie Bai, Ming Liu, Hongbao Li, Yangping Li, Li Yu, Yan Shou, Meilan Jing, Rui Zhao, Liyuan Huang, Chen Wang, Hanmin Ann Saudi Med Original Article BACKGROUND AND OBJECTIVES: The evidence for high-volume hemofiltration plus hemoperfusion (HVHF&HP) for hyperlipidemic severe acute pancreatitis (HL-SAP) is anecdotal. The purpose of our study was to evaluate the efficacy of HVHF&HP for HL-SAP in a prospective controlled study. DESIGN AND SETTING: Prospective controlled pilot study between May 2010 and May 2013 in a hospital intensive care unit. PATIENTS AND METHODS: HL-SAP patients chose conventional treatment alone (the control group) or conventional treatment combined with the experimental protocol (the HVHF&HP group) and were prospectively followed in our hospital. APACHE II score, SOFA score, ICU and hospital stay duration, and serum biomarkers were considered endpoints. RESULTS: Ten HL-SAP patients accepted conventional treatment alone (the control group) and 10 patients underwent HVHF&HP combined with conventional treatment (the HVHF&HP group). The APACHE II score, SOFA score, systolic blood pressure, diastolic blood pressure, heart rate, serum amylase, and serum creatinine were significantly reduced after the HVHF&HP treatment. The changes in these variables were significantly different between the HVHF&HP and control group at 48 hours after the initiation of treatment. Patients in the HVHF&HP group had a significantly shorter ICU stay (P=.015). The reduction in serum triglyceride and cholesterol in the HVHF&HP group after 2, 6, 12, 24, and 48 hours was greater than the control group. All of the tested serum cytokines were significantly decreased after HVHF&HP treatment (P<.05). However, in patients who underwent conventional treatment alone, there was no significant change in the serum cytokines. CONCLUSION: This study suggests that the addition of HVHF&HP to conventional treatment for HL-SAP patients may be superior to conventional treatment alone for the improvement of serum biomarkers and clinical outcomes. King Faisal Specialist Hospital and Research Centre 2015 /pmc/articles/PMC6074380/ /pubmed/26506968 http://dx.doi.org/10.5144/0256-4947.2015.352 Text en Copyright © 2015, Annals of Saudi Medicine This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Sun, Shiren
He, Lijie
Bai, Ming
Liu, Hongbao
Li, Yangping
Li, Li
Yu, Yan
Shou, Meilan
Jing, Rui
Zhao, Liyuan
Huang, Chen
Wang, Hanmin
High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study
title High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study
title_full High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study
title_fullStr High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study
title_full_unstemmed High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study
title_short High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study
title_sort high-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074380/
https://www.ncbi.nlm.nih.gov/pubmed/26506968
http://dx.doi.org/10.5144/0256-4947.2015.352
work_keys_str_mv AT sunshiren highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT helijie highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT baiming highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT liuhongbao highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT liyangping highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT lili highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT yuyan highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT shoumeilan highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT jingrui highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT zhaoliyuan highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT huangchen highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy
AT wanghanmin highvolumehemofiltrationplushemoperfusionforhyperlipidemicsevereacutepancreatitisacontrolledpilotstudy